News Pfizer, Arvinas join SERD club with Veppanu approval Arvinas and Pfizer's Veppanu is the first PROTAC – and third oral SERD for breast cancer – to be approved by the FDA.
News Moderna's Q1 revenues rocket, thanks to ex-US sales Moderna saw its Q1 sales nearly triple to $389m, almost a threefold rise on the same period of 2025, with international markets driving the increase.
News Axsome breaks new ground in Alzheimer's with Auvelity OK Axsome's Auvelity has become the first non-antipsychotic therapy for agitation in patients with Alzheimer's disease to be approved by the FDA.
News GLP-1s drive Lilly's Q1, but it's reticent on oral launch Investors are itching for news on the rollout of Lilly's oral weight-loss drug Foundayo, but there's little information in its first-quarter update.
News Norgine gets first EU approval for WHIM syndrome therapy Patients in the EU with the ultra-rare disease WHIM syndrome now have their first approved treatment, Norgine's Xolremdi.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
R&D Sponsored From Alzheimer’s disease research to the real-world setting:... In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
